Natus Medical Inc. (NASDAQ:BABY) shares traded down 2.2% on Monday . The stock traded as low as $37.89 and last traded at $37.92, with a volume of 82,055 shares. The stock had previously closed at $38.79.

Several research analysts recently weighed in on the stock. Roth Capital reaffirmed a “buy” rating on shares of Natus Medical in a report on Thursday, April 21st. Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a report on Thursday, July 7th.

The company has a 50 day moving average of $38.59 and a 200 day moving average of $35.59. The company has a market cap of $1.23 billion and a price-to-earnings ratio of 32.78.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.03. The company earned $96 million during the quarter, compared to analysts’ expectations of $92.71 million. During the same period in the prior year, the business posted $0.34 EPS. The company’s quarterly revenue was up 4.5% on a year-over-year basis. On average, equities analysts forecast that Natus Medical Inc. will post $1.68 earnings per share for the current year.

Several hedge funds and institutional investors have modified their holdings of BABY. California Public Employees Retirement System boosted its position in shares of Natus Medical by 1.2% in the fourth quarter. California Public Employees Retirement System now owns 165,145 shares of the company’s stock valued at $7,935,000 after buying an additional 2,000 shares during the period. Morgan Stanley boosted its position in shares of Natus Medical by 108.0% in the fourth quarter. Morgan Stanley now owns 242,583 shares of the company’s stock valued at $11,656,000 after buying an additional 125,964 shares during the period. Bank of Montreal Can boosted its position in shares of Natus Medical by 438.3% in the fourth quarter. Bank of Montreal Can now owns 66,692 shares of the company’s stock valued at $3,205,000 after buying an additional 54,303 shares during the period. Wells Fargo & Company MN boosted its position in shares of Natus Medical by 533.8% in the fourth quarter. Wells Fargo & Company MN now owns 406,530 shares of the company’s stock valued at $19,534,000 after buying an additional 342,390 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of Natus Medical by 6.5% in the fourth quarter. Principal Financial Group Inc. now owns 222,296 shares of the company’s stock valued at $10,682,000 after buying an additional 13,504 shares during the period.

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.